Recent advances in cancer immunotherapy, including the development of immune checkpoint blockades (ICBs), such as those targeting PD-1, PD-L1, and CTLA-4, have resulted in a paradigm shift in cancer treatment. The gene discussed is CD274; the disease is cancer.